ARG2 and hypertensive disorder: Our previous study showed that a subcutaneous infusion of Ang II (1 mg/kg/day, 28 days) in mice causes elevated vascular arginase expression and activity, impaired endothelium-dependent vasorelaxation and hypertension that are prevented by co-treatment with the arginase inhibitor BEC (boronoethyl cysteine) or in ARG1+/-ARG2-/- knockout mice [4].